LDN-193189 | B3067

LDN-193189 inhibits the activity of the Bone Morphogenetic Protein (BMP) type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM respectively and shows weaker effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7 (IC₅₀≥ 500 nM). It inhibits the activation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 in a dose-dependent manner in C2C12 cells. LDN-193189 significantly reduces tumor growth in SCID mice bearing MDA-PCa-118b tumors.

LDN-193189 inhibits the activity of the Bone Morphogenetic Protein (BMP) type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM respectively and shows weaker effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7 (IC₅₀≥ 500 nM). It inhibits the activation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 in a dose-dependent manner in C2C12 cells. LDN-193189 significantly reduces tumor growth in SCID mice bearing MDA-PCa-118b tumors.

B3067 | LDN-193189 DataSheet

Alternate Name/Synonyms: 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline,DM-3189

Appearance: Light yellow to yellow powder

Formulation:

CAS Number: 1062368-24-4

Structure Available?: TRUE

Peptide sequence:

Salt Form: FALSE

Molecular Formula: C₂₅H₂₂N₆

Molecular Weight: 406.5

Cell-Permeable?: TRUE

Purity: ≥98%

Solubilities: 0.2 mg/ml in ethanol (may need warming and sonication)

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: An inhibitor of BMP receptor 1

MDL Number: MFCD17169988

PubChem CID: 25195294

SMILES: C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3

InChi: InChI=1S/C25H22N6/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2

InChi Key: CDOVNWNANFFLFJ-UHFFFAOYSA-N